COMMUNIQUÉS West-GlobeNewswire

Anika Reports First Quarter 2024 Financial Results
08/05/2024
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the [...]
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
08/05/2024
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of [...]
Terns Pharmaceuticals Announces Leadership Changes
08/05/2024
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
08/05/2024
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling [...]
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
08/05/2024
Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track [...]
RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA(1) and Adjusted Earnings(3) and Revises Upwards 2024 Financial Guidance Ranges
08/05/2024
Total Company Revenue increased 10.5% to $431.7 million in the first quarter of 2024 from $390.6 million in the first quarter of 2023; Revenue from the Digital Health reportable segment increased 32.3% to $14.7 million [...]
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
08/05/2024
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by [...]
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company’s term loan by one year to September 30, 2026 -- -- Maintained full-year 2024 revenue [...]
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08/05/2024
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based [...]
electroCore Announces First Quarter 2024 Financial Results
08/05/2024
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE [...]
Apollomics Announces Private Placement Financing and Addition to Board of Directors
08/05/2024
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment- [...]
LifeMD Reports First Quarter 2024 Results; Raises Full Year Revenue Guidance
08/05/2024
First quarter revenue increased 33% year-over-year to $44.1 million with telehealth revenue growing 53% versus the year-ago period. Raising full-year revenue guidance to at least $205 million, up from prior guidance of [...]
RxSight, Inc. Announces Proposed Public Offering of Common Stock
08/05/2024
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
08/05/2024
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect [...]
Maravai LifeSciences Reports First Quarter 2024 Financial Results
08/05/2024
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of [...]
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX- [...]
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
08/05/2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 [...]
Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
08/05/2024
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
08/05/2024
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) Oculis also aims to complete an IND submission for OCS-05 in the U.S [...]

Pages